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Summary
A rare germline variant in the MITF (microphthalmia-associated transcription factor) gene,
E318K, has been reported as associated with melanoma. We confirmed its independent association
with melanoma (odds ratio (OR) 1.7, 95% Confidence Interval (CI) = 1.1, 2.7, p = 0.03); adjusted
for age, sex, center, age*sex interaction, pigmentation characteristics, family history of melanoma
and nevus density). In stratified analyses, carriage of MITF E318K was associated with melanoma
more strongly in people with dark hair than fair hair (p for interaction, 0.03) and in those with no
moles than some or many moles (p for interaction, <0.01). There was no evidence of interaction
between MC1R “red hair variants” and MITF E318K. Moreover, risk of melanoma among carriers
with “low risk” phenotypes was as great or greater than among those with “at risk” phenotypes
with few exceptions.
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MITF, the microphthalmia-associated transcription factor, is critical for lineage commitment
of undifferentiated, immature neural crest cells to mature, melanin-producing melanocytes
(Goding, 2000). UV exposure to the epidermis promotes alpha-MSH release, which then
binds to the melanocortin-1 receptor (MC1R), a transmembrane G-protein-coupled receptor
located on the cell membrane of melanocytes. This binding culminates in the activation of
the M-isoform of MITF, termed MITF-M, expressed in melanocytes through a cAMP-
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mediated signaling pathway (Haq and Fisher, 2011; Fuse et al., 1996). The activation of
MITF, in turn, induces the transcription of pigmentation-related genes, which produce
eumelanin that protects cells from UV damage (Cheli et al., 2009). Other MITF functions
may be based on the fact that several MITF-target genes regulate cell cycle and survival
(Cheli et al., 2010), and MITF appears to protect against oxidative stress (Liu et al., 2009).
The E318K variant of MITF (rs149617956) is a functional and rare variant that is associated
with melanoma risk. It is located in a small-ubiquitin-like modifier (SUMO) consensus site
and the missense variant impairs the SUMOylation of MITF, leading to the binding of MITF
and the transcriptional regulation of MITF’s target genes. In a large Australian case-control
study of 2,059 melanoma cases and in a UK case-control study of 1,929 cases, the E318K
variant conferred a 2.2-fold risk for developing melanoma (Yokoyama et al., 2011). Among
a sample of 586 French melanoma patients, genetically enriched for melanoma and renal
cell carcinoma, a 4.8-fold increased risk of melanoma was observed in MITF variant carriers
(Bertolotto et al., 2011). An Italian study of 667 patients in a clinic setting found a 2.9-fold
increased risk for melanoma, which was greater with nodular than with other histological
types of melanoma (Ghiorzo et al., 2013). They also observed positive associations of the
variant with personal or family history of renal cell or pancreatic cancer.
The prevalence of the MITF E318K minor allele variant among melanoma cases is low:
0.017 in Australia; 0.018 in the UK; 0.016 in France; and 0.009 in Italy (Yokoyama et al.,
2011; Bertolotto et al., 2011; Ghiorzo et al., 2013). Our large international, multicenter
melanoma case control study, GEM, was designed especially to identify the effects of rare
genetic variants in melanoma (Begg and Berwick, 1997). A detailed description of the
methods used in this study is available elsewhere (Begg et al., 2006). It was conducted in
nine centers in four countries--Australia, Italy, Canada and the United States. Institutional
review board approval was obtained from all centers. Written informed consent was
obtained prior to interview.
In GEM, patients newly diagnosed with a second or higher order primary melanoma are
cases, and individuals newly diagnosed with a first primary melanoma are controls; this
design produces similar results to classic case-control studies, but with greater statistical
power to detect effects of rare risk factors (Begg and Berwick, 1997). We assessed MITF
E318K in 1,194 cases and 2,430 controls. It was genotyped by mass spectrometry with the
MassArray iPLEX genotyping platform (Sequenom Inc, San Diego, CA). Quality control
included use of internal negative controls, sequencing of selected samples to confirm
specificity, and agreement between blinded duplicates (Orlow et al., 2012). All statistical
tests were two-sided with P < 0.05 considered statistically significant. All data were
analyzed using SAS 9.3 (Cary, NC). There were 97 carriers of the E138K variant, 44 (3.7%)
among the 1,194 cases and 53 (2.2%) among the 2,430 controls. The minor allele frequency
was 0.014 among all melanoma patients, similar to other studies noted above.
Presence of MITF E318K was significantly associated with risk for melanoma (OR 1.7, 95
% CI 1.1, 2.6, p = 0.02) in a logistic regression model adjusted for the design variables: age
at diagnosis, sex, age*sex interaction, and recruitment center. This association is similar in
strength to that observed in the Australian and UK studies described above. After further
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adjustment for pigmentation characteristics, family history of melanoma, and nevus density,
the OR remained as 1.7 (95% CI = 1.1, 2.7, p = 0.03).
Odds ratios for the association of MITF E318K with melanoma in categories of other
melanoma risk factors (which have been shown to be associated with melanoma in this
study (Begg et al., 2006) are shown in Table 1. Increased risk of melanoma with carriage of
MITF E318K appeared to be strongest among those with traditionally low risk phenotypes:
“nonblue” eyes, black/dark brown hair, absence of moles, absence of freckling in youth and
absence of a family history of melanoma (Table 1) This effect modification, though, was
significant only for mole count and hair color. However, although the interaction is
significant, red hair color had an odds ratio of 3.1 (95% CI 0.9, 10.8), so this association
needs further study. When evaluating the mole count in relationship to the MITF variant, it
can be seen that our results are similar to those reported by Yokoyama et al. (2011), where
there is a significant trend among single primary melanomas, our controls, for the
association between mole count and the presence of the variant E318K in MITF (p = 0.04)
The well-established effects of MC1R variants on risk of melanoma are similar to those we
have found for MITF E318K, in being independent of the classical melanoma risk factors.
Sturm et al. (2013) suggest the potential for an interaction between MC1R “R” variants and
the MITF variant. However, we have found no evidence of such (either as the traditional “R”
variants – D84E, R151C, R160W and D294H – or as these four, including R142H plus stop
variants and indels that result in frameshifts and premature stop codons—or as “any” MC1R
variant) with the presence of the MITF variant E318K. We also evaluated the role of such an
interaction on pigmentation of the melanoma (amelanotic or pigmented) and found no
association. It is likely that both have extra-pigmentary effects that are independent, and
stronger in people with dark hair than those with light hair (Demenais et al., 2010; Kanetsky
et al., 2011; Egan et al., 2003; Ozolo et al., 2013; Cust et al., 2012). These similarities are
consistent with the fact that both genes act in the pathway from UV exposure to eumelanin
production. The complexities of this pathway’s role in melanomagenesis merit further
investigation.
The modification of effects of MCIR “R” variants and MITF E318K within strata of
classical melanoma risk factors suggests that these genetic variants may also be valuable in
predicting risk of melanoma in people without classical risk factors and that this information
could help in public health and clinical prevention strategies.
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These relationships with melanoma risk factors suggest that MITF E318K is a genetic
risk factor that may be valuable in predicting risk of melanoma in people without classic
risk factors for melanoma such as fair hair and multiple nevi and that this information
may help with public health and clinical prevention strategies.
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